

SENATE SUBSTITUTE
FOR
SENATE COMMITTEE SUBSTITUTE
FOR
SENATE BILLS NOS. 865 & 866

AN ACT

To repeal sections 338.270 and 338.347, RSMo, and to enact in lieu thereof five new sections relating to pharmacy.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF MISSOURI,
AS FOLLOWS:

1 Section A. Sections 338.270 and 338.347, RSMo, are repealed
2 and five new sections enacted in lieu thereof, to be known as
3 sections 338.075, 338.270, 338.347, 376.379, and 376.388, to read
4 as follows:

5 338.075. 1. All licensees, registrants, and permit holders
6 of the board shall report to the board:

7 (1) Any final adverse action taken by another licensing
8 state, jurisdiction, or government agency against any license,
9 permit, or authorization held by the person or entity to practice
10 or operate as a pharmacist, intern pharmacist, pharmacy
11 technician, pharmacy, drug distributor, drug manufacturer, or
12 drug outsourcing facility. For purposes of this section,
13 "adverse action" shall include, but is not limited to,
14 revocation, suspension, censure, probation, disciplinary
15 reprimand, or disciplinary restriction of a license, permit, or
16 other authorization or a voluntary surrender of such license,

1 permit, or other authorization in lieu of discipline or adverse
2 action;

3 (2) Any surrender of a license or authorization to practice
4 or operate as a pharmacist, intern pharmacist, pharmacy
5 technician, pharmacy, drug distributor, drug manufacturer, or
6 drug outsourcing facility while under disciplinary investigation
7 by another licensing state, jurisdiction, or governmental agency,
8 and;

9 (3) Any exclusion to participate in any state or federally
10 funded health care program such as Medicare, Medicaid, or MO
11 HealthNet for fraud, abuse, or submission of any false or
12 fraudulent claim, payment, or reimbursement request.

13 2. Reports shall be submitted as provided by the board by
14 rule.

15 3. The board shall promulgate rules to implement the
16 provisions of this section. Any rule or portion of a rule, as
17 that term is defined in section 536.010 that is created under the
18 authority delegated in this section shall become effective only
19 if it complies with and is subject to all of the provisions of
20 chapter 536, and, if applicable, section 536.028. This section
21 and chapter 536 are nonseverable and if any of the powers vested
22 with the general assembly pursuant to chapter 536, to review, to
23 delay the effective date, or to disapprove and annul a rule are
24 subsequently held unconstitutional, then the grant of rulemaking
25 authority and any rule proposed or adopted after August 28, 2016,
26 shall be invalid and void.

27 338.270. 1. Application blanks for renewal permits shall
28 be mailed to each permittee on or before the first day of the

1 month in which the permit expires and, if application for renewal
2 of permit is not made before the first day of the following
3 month, the existing permit, or renewal thereof, shall lapse and
4 become null and void upon the last day of that month.

5 2. The board shall not renew a nonresident pharmacy license
6 if the renewal applicant does not hold a current pharmacy license
7 or its equivalent in the state in which the nonresident pharmacy
8 is located.

9 338.347. 1. Application blanks for renewal of license
10 shall be mailed to each licensee on or before the first day of
11 the month in which the license expires and, if application for
12 renewal of license with required fee is not made before the first
13 day of the following month, the existing license, or renewal
14 thereof, shall lapse and become null and void upon the last day
15 of that month.

16 2. The board shall not renew an out-of-state wholesale drug
17 distributor, out-of-state pharmacy distributor, or drug
18 distributor license or registration if the renewal applicant does
19 not hold a current distributor license or its equivalent in the
20 state or jurisdiction in which the distribution facility is
21 located, or, if a drug distributor registrant, the entity is not
22 authorized and in good standing to operate as a drug manufacturer
23 with the Food and Drug Administration or within the state or
24 jurisdiction where the facility is located.

25 376.379. 1. A health carrier or managed care plan offering
26 a health benefit plan in this state that provides prescription
27 drug coverage shall offer, as part of the plan, medication
28 synchronization services developed by the health carrier or

1 managed care plan that allow for the alignment of refill dates
2 for an enrollee's prescription drugs that are covered benefits.

3 2. Under its medication synchronization services, a health
4 carrier or managed care plan shall:

5 (1) Not charge an amount in excess of the otherwise
6 applicable copayment amount under the health benefit plan for
7 dispensing a prescription drug in a quantity that is less than
8 the prescribed amount if:

9 (a) The pharmacy dispenses the prescription drug in
10 accordance with the medication synchronization services offered
11 under the health benefit plan; and

12 (b) A participating provider dispenses the prescription
13 drug;

14 (2) Provide a full dispensing fee to the pharmacy that
15 dispenses the prescription drug to the covered person.

16 3. For the purposes of this section the terms "health
17 carrier", "managed care plan", "health benefit plan", "enrollee",
18 and "participating provider" shall have the same meaning as
19 defined in section 376.1350.

20 376.388. 1. As used in this section, unless the context
21 requires otherwise, the following terms shall mean:

22 (1) "Contracted pharmacy" or "pharmacy", a pharmacy located
23 in Missouri participating in the network of a pharmacy benefits
24 manager through a direct or indirect contract;

25 (2) "Health carrier", an entity subject to the insurance
26 laws and regulations of this state that contracts or offers to
27 contract to provide, deliver, arrange for, pay for, or reimburse
28 any of the costs of health care services, including a sickness

and accident insurance company, a health maintenance organization, a nonprofit hospital and health service corporation, or any other entity providing a plan of health insurance, health benefits, or health services, except that such plan shall not include any coverage pursuant to a liability insurance policy, workers' compensation insurance policy, or medical payments insurance issued as a supplement to a liability policy;

(3) "Maximum allowable cost", the per unit amount that a pharmacy benefits manager reimburses a pharmacist for a prescription drug, excluding a dispensing or professional fee;

(4) "Maximum allowable cost list" or "MAC list", a listing of drug products that meet the standard described in this section;

(5) "Pharmacy", as such term is defined in chapter 338;

(6) "Pharmacy benefits manager", an entity that contracts with pharmacies on behalf of health carriers or any health plan sponsored by the state or a political subdivision of the state.

2. Upon each contract execution or renewal between a pharmacy benefits manager and a pharmacy or between a pharmacy benefits manager and a pharmacy's contracting representative or agent, such as a pharmacy services administrative organization, a pharmacy benefits manager shall, with respect to such contract or renewal:

(1) Include in such contract or renewal the sources utilized to determine maximum allowable cost and update such pricing information at least every seven days; and

(2) Maintain a procedure to eliminate products from the

1 maximum allowable cost list of drugs subject to such pricing or
2 modify maximum allowable cost pricing at least every seven days
3 if such drugs do not meet the standards and requirements of this
4 section in order to remain consistent with pricing changes in the
5 marketplace.

6 3. A pharmacy benefits manager shall reimburse pharmacies
7 for drugs subject to maximum allowable cost pricing which has
8 been updated to reflect market pricing at least every seven days
9 as set forth in subdivision (1) of subsection 2 of this section.

10 4. A pharmacy benefits manager shall not place a drug on a
11 maximum allowable cost list unless there are at least two
12 therapeutically equivalent multi-source generic drugs, or at
13 least one generic drug available from at least one manufacturer,
14 generally available for purchase by network pharmacies from
15 national or regional wholesalers.

16 5. All contracts between a pharmacy benefits manager and a
17 contracted pharmacy or between a pharmacy benefits manager and a
18 pharmacy's contracting representative or agent, such as a
19 pharmacy services administrative organization, shall include a
20 process to internally appeal, investigate, and resolve disputes
21 regarding maximum allowable cost pricing. The process shall
22 include the following:

23 (1) The right to appeal shall be limited to fourteen
24 calendar days following the reimbursement of the initial claim;
25 and

26 (2) A requirement that the pharmacy benefits manager shall
27 respond to an appeal described in this subsection no later than
28 fourteen calendar days after the date the appeal was received by

1 such pharmacy benefits manager.

2 6. For appeals that are denied, the pharmacy benefits
3 manager shall provide the reason for the denial and identify the
4 national drug code of a drug product that may be purchased by
5 contracted pharmacies at a price at or below the maximum
6 allowable cost, and when applicable, may be substituted lawfully.

7 7. If the appeal is successful, the pharmacy benefits
8 manager shall:

9 (1) Adjust the maximum allowable cost price that is the
10 subject of the appeal effective on the day after the date the
11 appeal is decided;

12 (2) Apply the adjusted maximum allowable cost price to all
13 similarly situated pharmacies as determined by the pharmacy
14 benefits manager; and

15 (3) Allow the pharmacy that succeeded in the appeal to
16 reverse and rebill the pharmacy benefits claim giving rise to the
17 appeal.

18 8. Appeals shall be upheld if:

19 (1) The pharmacy being reimbursed for the drug subject to
20 the maximum allowable cost pricing in question was not reimbursed
21 as required in subsection 3 of this section; or

22 (2) The drug subject to the maximum allowable cost pricing
23 in question does not meet the requirements set forth in
24 subsection 4 of this section.